Published in Sci Transl Med on November 09, 2011
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother (2012) 1.54
Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis. Cells (2014) 1.49
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A (2013) 1.11
Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med (2013) 1.02
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol (2013) 0.98
Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays. J Immunol Methods (2014) 0.98
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother (2012) 0.98
The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology (2012) 0.97
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems. Alzheimers Res Ther (2013) 0.94
Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther (2015) 0.92
Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials. PLoS One (2013) 0.90
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol Immunother (2012) 0.88
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol Immunother (2012) 0.86
Profiling the immune stromal interface in breast cancer and its potential for clinical impact. Breast Care (Basel) (2012) 0.85
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunol Immunother (2015) 0.83
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer (2014) 0.83
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. Cytometry A (2014) 0.81
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer (2016) 0.81
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int (2013) 0.80
Managing Multi-center Flow Cytometry Data for Immune Monitoring. Cancer Inform (2015) 0.80
Immunological Monitoring to Rationally Guide AAV Gene Therapy. Front Immunol (2013) 0.79
Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies. J Immunol Methods (2014) 0.77
The effects of storage temperature on PBMC gene expression. BMC Immunol (2016) 0.77
Structured reporting of T cell assay results. Cancer Immun (2013) 0.77
Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget (2017) 0.77
Ancillary study management systems: a review of needs. BMC Med Inform Decis Mak (2013) 0.76
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring. Oncoimmunology (2012) 0.76
A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics. Alzheimers Res Ther (2016) 0.75
Estimating point and interval frequency of antigen-specific CD4+ T cells based on short in vitro expansion and improved poisson distribution analysis. PLoS One (2012) 0.75
A framework for T cell assays. Oncotarget (2015) 0.75
Harmonization of Clinical Laboratory Information - Current and Future Strategies. EJIFCC (2016) 0.75
Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform. BMC Bioinformatics (2013) 0.75
Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring. J Transl Med (2016) 0.75
Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells. Front Immunol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
The Pathway Tools software. Bioinformatics (2002) 14.89
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods (2002) 4.48
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood (2013) 2.39
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93
EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem (2006) 1.91
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci (2007) 1.87
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol (2009) 1.81
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
D²P²: database of disordered protein predictions. Nucleic Acids Res (2012) 1.75
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol (2008) 1.70
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood (2012) 1.64
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood (2014) 1.64
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol (2002) 1.62
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine (2007) 1.58
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods (2006) 1.57
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Rational drug design via intrinsically disordered protein. Trends Biotechnol (2006) 1.57
More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol (2011) 1.56
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med (2002) 1.53
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res (2013) 1.51
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics (2014) 1.50
Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol (2004) 1.47
Transcriptional profiling of Caulobacter crescentus during growth on complex and minimal media. J Bacteriol (2004) 1.46
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene (2002) 1.42
Conservation of intrinsic disorder in protein domains and families: I. A database of conserved predicted disordered regions. J Proteome Res (2006) 1.42
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med (2003) 1.41
Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat (2012) 1.39
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38